Nayuta Tsushima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nayuta Tsushima has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Satoshi Kano
Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
5 shared publicationsTakayoshi Suzuki
Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
4 shared publications- Akihiro Homma
Department of Otolaryngology-Head & Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-Ku, N15W7, Sapporo 0608638, Hokkaido, Japan
3 shared publications Hiroshi Idogawa
Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
3 shared publicationsSeijiro Hamada
Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan; Department of Otorhinolaryngology, Steel Memorial Muroran Hospital, Hokkaido, Japan
3 shared publicationsAkihiro Homma
Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
2 shared publications
Latest Publications
- 1 June 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (7) , 1326-1335
Resting heart rate as a prognostic indicator for patients with head and neck squamous cell carcinoma
Background Elevated resting heart rate (RHR) has been associated with poor prognosis in various cancers, but its significance in head and neck cancer (HNC) remains unclear. This study aimed to evaluate the prognostic impact of RHR and its association with the incidence of second primary cancer (SPC). Methods We retrospectively analyzed 213 patients with oropharyngeal, hypopharyngeal, or laryngeal squamous cell carcinoma who underwent chemoradiotherapy. Pretreatment RHR was measured from electrocardiograms, and survival outcomes were analyzed using Kaplan-Meier and Cox regression models. Results Patients with an RHR ≥ 83 bpm had significantly worse overall survival (P = 0.004) and disease-specific survival (P < 0.001). Elevated RHR was an independent prognostic factor and was associated with an increased incidence of SPC (P = 0.016), particularly esophageal cancer (P = 0.003). In exploratory analyses, this association with esophageal SPC remained after adjustment for alcohol consumption category and smoking status. Conclusions RHR is a potential prognostic marker in HNC and, in exploratory analyses, was associated with an increased risk of SPCs, particularly esophageal cancer. These findings suggest that RHR may help stratify risk in patients with HNC, although further studies are needed to clarify its clinical implications.
- 1 June 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (7) , 1326-1335
Resting heart rate as a prognostic indicator for patients with head and neck squamous cell carcinoma
Background Elevated resting heart rate (RHR) has been associated with poor prognosis in various cancers, but its significance in head and neck cancer (HNC) remains unclear. This study aimed to evaluate the prognostic impact of RHR and its association with the incidence of second primary cancer (SPC). Methods We retrospectively analyzed 213 patients with oropharyngeal, hypopharyngeal, or laryngeal squamous cell carcinoma who underwent chemoradiotherapy. Pretreatment RHR was measured from electrocardiograms, and survival outcomes were analyzed using Kaplan-Meier and Cox regression models. Results Patients with an RHR ≥ 83 bpm had significantly worse overall survival (P = 0.004) and disease-specific survival (P < 0.001). Elevated RHR was an independent prognostic factor and was associated with an increased incidence of SPC (P = 0.016), particularly esophageal cancer (P = 0.003). In exploratory analyses, this association with esophageal SPC remained after adjustment for alcohol consumption category and smoking status. Conclusions RHR is a potential prognostic marker in HNC and, in exploratory analyses, was associated with an increased risk of SPCs, particularly esophageal cancer. These findings suggest that RHR may help stratify risk in patients with HNC, although further studies are needed to clarify its clinical implications.
- 18 June 2025
- Published by Elsevier in Auris Nasus Larynx
- Vol. 52 (4) , 398-403
Running pattern of the internal maxillary artery assessed using arterial-phase CT images in 434 sides in Japanese individuals
- 18 June 2025
- Published by Elsevier in Auris Nasus Larynx
- Vol. 52 (4) , 398-403
Running pattern of the internal maxillary artery assessed using arterial-phase CT images in 434 sides in Japanese individuals
- 10 November 2023
- Published by Elsevier in Auris Nasus Larynx
- Vol. 51 (2) , 313-319
Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations
- 10 November 2023
- Published by Elsevier in Auris Nasus Larynx
- Vol. 51 (2) , 313-319
Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations
- 17 June 2023
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 28 (9) , 1218-1226
Treatment outcomes of the patient with sinonasal mucosal melanoma: the role of endoscopic resection and postoperative radiotherapy
Background The standard of care for sinonasal mucosal melanoma is surgery and postoperative radiotherapy (PORT). Our treatment strategy comprises endoscopic resection and PORT. We performed combined endoscopic and open resection or applied an external approach alone when sufficient resection was difficult to achieve endoscopically. The objective of this study was to evaluate the validity of our treatment strategy. Methods We assessed 30 patients with sinonasal mucosal melanoma who underwent definitive therapy between January 2002 and April 2021, and conducted a retrospective analysis. The median follow-up period was 2.2 years. The primary endpoint was overall survival. The Kaplan–Meier method was used for the calculation of survival rates, the cumulative incidence of distant metastasis, and local recurrence. Results Twenty-eight patients underwent surgery. The other two patients were treated by definitive proton beam therapy. Twenty-one of 28 (75%) patients underwent resection by endoscopic approach alone. Postoperative radiotherapy was performed for all 28 patients who underwent surgery. Twenty-one patients (70%) experienced recurrence during the observation period. Overall, distant metastasis was observed in 19 patients. Twelve patients died during the observation period, with 10 of the 12 patients (83%) dying of distant metastasis. The overall survival rate at 2 and 5 years was 70% and 46%, respectively. The cumulative incidence rate of distant metastasis at 2 years was 63%, while the 2-year cumulative incidence rate of local recurrence was 6.7%. Conclusion The local disease was controlled by our treatment strategy. To improve treatment outcomes, control of the distant metastasis is needed.
- 17 June 2023
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 28 (9) , 1218-1226
Treatment outcomes of the patient with sinonasal mucosal melanoma: the role of endoscopic resection and postoperative radiotherapy
Background The standard of care for sinonasal mucosal melanoma is surgery and postoperative radiotherapy (PORT). Our treatment strategy comprises endoscopic resection and PORT. We performed combined endoscopic and open resection or applied an external approach alone when sufficient resection was difficult to achieve endoscopically. The objective of this study was to evaluate the validity of our treatment strategy. Methods We assessed 30 patients with sinonasal mucosal melanoma who underwent definitive therapy between January 2002 and April 2021, and conducted a retrospective analysis. The median follow-up period was 2.2 years. The primary endpoint was overall survival. The Kaplan–Meier method was used for the calculation of survival rates, the cumulative incidence of distant metastasis, and local recurrence. Results Twenty-eight patients underwent surgery. The other two patients were treated by definitive proton beam therapy. Twenty-one of 28 (75%) patients underwent resection by endoscopic approach alone. Postoperative radiotherapy was performed for all 28 patients who underwent surgery. Twenty-one patients (70%) experienced recurrence during the observation period. Overall, distant metastasis was observed in 19 patients. Twelve patients died during the observation period, with 10 of the 12 patients (83%) dying of distant metastasis. The overall survival rate at 2 and 5 years was 70% and 46%, respectively. The cumulative incidence rate of distant metastasis at 2 years was 63%, while the 2-year cumulative incidence rate of local recurrence was 6.7%. Conclusion The local disease was controlled by our treatment strategy. To improve treatment outcomes, control of the distant metastasis is needed.
- 10 October 2022
- Published by Elsevier in Auris Nasus Larynx
- Vol. 50 (3) , 423-429
Pretreatment elevated mean corpuscular volume as an indicator for high risk esophageal second primary cancer in patients with head and neck cancer
- 10 October 2022
- Published by Elsevier in Auris Nasus Larynx
- Vol. 50 (3) , 423-429
Pretreatment elevated mean corpuscular volume as an indicator for high risk esophageal second primary cancer in patients with head and neck cancer
- Open Access
- 1 January 2020
- Published by SAGE Publications in Clinical Medicine Insights: Case Reports
- Vol. 13
Salvage Reconstructive Surgery During Nivolumab Therapy for a Patient With Hypopharyngeal Cancer
Objectives: Nivolumab, a fully IgG4-programmed death-1 inhibitor antibody, led to improved overall survival compared with single-agent therapy in patients with platinum-refractory recurrent head and neck cancers. In general, nivolumab is used in inoperable patients. To the best of our knowledge, there have been no reports of salvage surgery during nivolumab therapy for patients with head and neck cancer. We report the case of a woman treated with salvage reconstructive surgery during nivolumab therapy. Method: Case report and literature review. Results: The patient underwent nivolumab therapy for recurrent primary and neck disease after induction chemotherapy, followed by concurrent chemoradiation therapy. The neck disease shrunk, whereas the primary disease temporarily shrunk but later progressed again. Recurrent primary disease led to a narrowing of her airway, and she required airway management. We performed total pharyngolaryngectomy with free jejunal reconstruction, and her quality of life improved. The surgery was performed without complications and the postoperative course was uneventful. She was discharged postoperative day 18 with oral intake function and a safer airway. Conclusion: As far as we know, this is the first report of salvage surgery during nivolumab therapy for patients with head and neck cancer. The salvage reconstructive surgery in this case proceeded uneventfully.
- 1 January 2020
- Published by SAGE Publications in Clinical Medicine Insights: Case Reports
- Vol. 13
Open AccessSalvage Reconstructive Surgery During Nivolumab Therapy for a Patient With Hypopharyngeal Cancer
Objectives: Nivolumab, a fully IgG4-programmed death-1 inhibitor antibody, led to improved overall survival compared with single-agent therapy in patients with platinum-refractory recurrent head and neck cancers. In general, nivolumab is used in inoperable patients. To the best of our knowledge, there have been no reports of salvage surgery during nivolumab therapy for patients with head and neck cancer. We report the case of a woman treated with salvage reconstructive surgery during nivolumab therapy. Method: Case report and literature review. Results: The patient underwent nivolumab therapy for recurrent primary and neck disease after induction chemotherapy, followed by concurrent chemoradiation therapy. The neck disease shrunk, whereas the primary disease temporarily shrunk but later progressed again. Recurrent primary disease led to a narrowing of her airway, and she required airway management. We performed total pharyngolaryngectomy with free jejunal reconstruction, and her quality of life improved. The surgery was performed without complications and the postoperative course was uneventful. She was discharged postoperative day 18 with oral intake function and a safer airway. Conclusion: As far as we know, this is the first report of salvage surgery during nivolumab therapy for patients with head and neck cancer. The salvage reconstructive surgery in this case proceeded uneventfully.
- 11 March 2019
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 49 (6) , 525-528
The role of elective neck dissection for cT4aN0 glottic squamous cell carcinoma
Objective The indication for elective neck dissection for patients with clinically T4aN0 (cT4aN0) glottic cancer is not established. The objective of this study was to evaluate the role of elective neck dissection for patients with cT4aN0 glottic cancer. Methods We assessed patients with cT4aN0 laryngeal squamous cell carcinoma who underwent total laryngectomy between 1998 and 2014 and conducted a retrospective analysis. We considered occult neck metastasis positive when confirmed by histological analysis. When patients with late neck metastases did not undergo therapeutic neck dissection, the presence of occult neck metastasis was judged on the basis of computed tomography. The validity of elective neck dissection for patients with cT4aN0 glottic cancer was assessed from comparisons the rates of occult neck metastases of supraglottic and subglottic cancers, which are generally recommended for elective neck dissection. The distribution of occult neck metastases in glottic cancer is described according to nodal levels. Results The rate of occult neck metastasis of cT4aN0 laryngeal cancer was 36% (14/39). There were no significant differences among the rates of glottic 7/21 (33%), supraglottic 3/8 (38%) and subglottic 4/10 (40%) cancers. Patients with glottic cancer did not have bilateral Level IIB and ipsilateral Level IV metastasis. One patient had contralateral Level IV metastasis. The metastases rates of ipsilateral Levels IIA, III, and VI were >10%. Conclusions We think that elective neck dissection is valid for cT4aN0 glottic cancer. Ipsilateral Levels IIA, III and VI should be dissected. The omission of neck dissection for bilateral Levels IIB and IV can be considered when there is a need to avoid complications.
- 11 March 2019
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 49 (6) , 525-528
The role of elective neck dissection for cT4aN0 glottic squamous cell carcinoma
Objective The indication for elective neck dissection for patients with clinically T4aN0 (cT4aN0) glottic cancer is not established. The objective of this study was to evaluate the role of elective neck dissection for patients with cT4aN0 glottic cancer. Methods We assessed patients with cT4aN0 laryngeal squamous cell carcinoma who underwent total laryngectomy between 1998 and 2014 and conducted a retrospective analysis. We considered occult neck metastasis positive when confirmed by histological analysis. When patients with late neck metastases did not undergo therapeutic neck dissection, the presence of occult neck metastasis was judged on the basis of computed tomography. The validity of elective neck dissection for patients with cT4aN0 glottic cancer was assessed from comparisons the rates of occult neck metastases of supraglottic and subglottic cancers, which are generally recommended for elective neck dissection. The distribution of occult neck metastases in glottic cancer is described according to nodal levels. Results The rate of occult neck metastasis of cT4aN0 laryngeal cancer was 36% (14/39). There were no significant differences among the rates of glottic 7/21 (33%), supraglottic 3/8 (38%) and subglottic 4/10 (40%) cancers. Patients with glottic cancer did not have bilateral Level IIB and ipsilateral Level IV metastasis. One patient had contralateral Level IV metastasis. The metastases rates of ipsilateral Levels IIA, III, and VI were >10%. Conclusions We think that elective neck dissection is valid for cT4aN0 glottic cancer. Ipsilateral Levels IIA, III and VI should be dissected. The omission of neck dissection for bilateral Levels IIB and IV can be considered when there is a need to avoid complications.